Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy

被引:720
作者
Stephenson, Andrew J.
Scardino, Peter T.
Kattan, Michael W.
Pisansky, Thomas M.
Slawin, Kevin M.
Klein, Eric A.
Anscher, Mitchell S.
Michalski, Jeff M.
Sandler, Howard M.
Lin, Daniel W.
Forman, Jeffrey D.
Zelefsky, Michael J.
Kestin, Larry L.
Roehrborn, Claus G.
Catton, Charles N.
DeWeese, Theodore L.
Liauw, Stanley L.
Valicenti, Richard K.
Kuban, Deborah A.
Pollack, Alan
机构
[1] Cleveland Clin Fdn, Glickman Urol Inst, Cleveland, OH 44195 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Mayo Clin, Coll Med, Rochester, MN USA
[4] Baylor Coll Med, Houston, TX 77030 USA
[5] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Univ Texas, SW Med Ctr, Dallas, TX USA
[7] Duke Univ, Sch Med, Durham, NC USA
[8] Washington Univ, Sch Med, St Louis, MO USA
[9] Univ Michigan, Med Ctr, Ann Arbor, MI USA
[10] Univ Washington, Sch Med, Seattle, WA USA
[11] Wayne State Univ, Sch Med, Detroit, MI USA
[12] William Beaumont Hosp, Royal Oak, MI 48072 USA
[13] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[14] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[15] Univ Florida, Coll Med, Gainesville, FL USA
[16] Thomas Jefferson Univ, Coll Med, Philadelphia, PA 19107 USA
[17] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
关键词
D O I
10.1200/JCO.2006.08.9607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose An increasing serum prostate-specific antigen (PSA) level is the initial sign of recurrent prostate cancer among patients treated with radical prostatectomy. Salvage radiation therapy (SRT) may eradicate locally recurrent cancer, but studies to distinguish local from systemic recurrence lack adequate sensitivity and specificity. We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence. Patients and Methods Using multivariable Cox regression analysis, we constructed a model to predict the probability of disease progression after SRT in a multi-institutional cohort of 1,540 patients. Results The 6-year progression-free probability was 32% (95% Cl, 28% to 35%) overall. Forty-eight percent (95% Cl, 40% to 56%) of patients treated with SRT alone at PSA levels of 0.50 ng/mL or lower were disease free at 6 years, including 41% (95% Cl, 31% to 51%) who also had a PSA doubling time of 10 months or less or poorly differentiated (Gleason grade 8 to 10) cancer. Significant variables in the model were PSA level before SRT (P <.001), prostatectomy Gleason grade (P <.001), PSA doubling time (P <.001), surgical margins (P <.001), androgen-deprivation therapy before or during SRT (P <.001), and lymph node metastasis (P =.019). The resultant nomogram was internally validated and had a concordance index of 0.69. Conclusion Nearly half of patients with recurrent prostate cancer after radical prostatectomy have a long-term PSA response to SRT when treatment is administered at the earliest sign of recurrence. The nomogram we developed predicts the outcome of SRT and should prove valuable for medical decision making for patients with a rising PSA level.
引用
收藏
页码:2035 / 2041
页数:7
相关论文
共 48 条
[1]   Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? [J].
Amling, CL ;
Bergstralh, EJ ;
Blute, ML ;
Slezak, JM ;
Zincke, H .
JOURNAL OF UROLOGY, 2001, 165 (04) :1146-1151
[2]   Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years [J].
Anscher, MS ;
Clough, R ;
Dodge, R .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (02) :369-375
[3]   Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function ("trifecta") [J].
Bianco, FJ ;
Scardino, PT ;
Eastham, JA .
UROLOGY, 2005, 66 (5A) :83-94
[4]  
BLUMBERG JW, 2004, ASCO NEWS, V16, pS4
[5]   Postoperative radiotherapy after radical prostatectomy:: a randomised controlled trial (EORTC trial 22911) [J].
Bolla, M ;
van Poppel, H ;
Collette, L ;
van Cangh, P ;
Vekemans, K ;
Da Pozzo, L ;
de Reijke, TM ;
Verbaeys, A ;
Bosset, JF ;
van Velthoven, R ;
Maréchal, JM ;
Scalliet, P ;
Haustermans, K ;
Piérart, M .
LANCET, 2005, 366 (9485) :572-578
[6]  
Brenner DJ, 2000, CANCER, V88, P398, DOI 10.1002/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0.CO
[7]  
2-V
[8]   Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy [J].
Lange, PH .
JOURNAL OF UROLOGY, 1998, 159 (01) :177-178
[9]   Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate [J].
Catton, C ;
Gospodarowicz, M ;
Warde, P ;
Panzarella, T ;
Catton, P ;
McLean, M ;
Milosevic, M .
RADIOTHERAPY AND ONCOLOGY, 2001, 59 (01) :51-60
[10]   Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy [J].
Cher, ML ;
Bianco, FJ ;
Lam, JS ;
Davis, LP ;
Grignon, DJ ;
Sakr, WA ;
Banerjee, M ;
Pontes, JE ;
Wood, DP .
JOURNAL OF UROLOGY, 1998, 160 (04) :1387-1391